Satralizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Demyelinating Diseases. According to GlobalData, Phase III drugs for Demyelinating Diseases have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Satralizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Satralizumab overview
Satralizumab (Enspryng) is a humanized monoclonal antibody. It is formulated as solution for subcutaneous route of administration. Enspryng is indicated for the treatment of adult and children's with neuromyelitis optica spectrum disorder (NMOSD) and uveitic macular edema. Enspryng is also indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult and adolescents patients who are anti-aquaporin-4 (AQP4) antibody positive.
See Also:
Satralizumab (SA-237) is under development for the treatment of neuromyelitis optica (NMO), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) autoimmune encephalitis, aneurysmal subarachnoid hemorrhage and NMO spectrum disorder and thyroid eye disease. It is administered subcutaneously as a solution. SA-237 is a humanized anti IL-6 receptor monoclonal antibody. It is a new molecular entity (NME). The drug candidate is developed from recycling antibody technology. It was also under development for the treatment of rheumatoid arthritis.
It is also under development for the treatment of myasthenia gravis.
F. Hoffmann-La Roche overview
F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, healthcare professionals, commercial laboratories, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.
For a complete picture of Satralizumab’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
